


Target product profiles (TPPs) for malaria medicines

Targets for malaria elimination and eradication

To reach aspirational targets...




...needs an innovative drug pipeline




Role of current and new antimalarials

Current medicines have helped us to control malaria in some areas....

...elimination/eradication demands better drugs.



Linking the TPPs to the target candidate profiles³ (TCPs)



Medicines for malaria eradication

<p>Blood-stage killers (TCP1)</p> <p>Adult dose 100 mg or less Active against all resistant strains</p>	<p>Hypnozoite killers (anti-relapse, TCP3)</p> <p>Kills hypnozoites with a single dose Safer than 8-aminoquinolines</p>	<p>Transmission blockers (gametocyticide, TCP5)</p> <p>Low dose for transmission reduction (less than for killing blood stages) Ideally adult dose 100 mg or less</p>
	<p>Chemoprotection (TCP 4)</p> <p>Kills liver schizonts with equal or lower dose than blood stages Ideally providing a once monthly protection</p>	<p>Transmission blockers (endectocide, TCP6)</p> <p>Ideally, once per season or once per month Low dose for transmission reduction (less than for killing blood stages)</p>

For more information on what makes a good medicine for eradication see Burrows *et al.*, 2017.